TW200616625A - Agent for prophylaxis or treatment of metabolic syndrome - Google Patents

Agent for prophylaxis or treatment of metabolic syndrome

Info

Publication number
TW200616625A
TW200616625A TW094134915A TW94134915A TW200616625A TW 200616625 A TW200616625 A TW 200616625A TW 094134915 A TW094134915 A TW 094134915A TW 94134915 A TW94134915 A TW 94134915A TW 200616625 A TW200616625 A TW 200616625A
Authority
TW
Taiwan
Prior art keywords
prophylaxis
agent
treatment
metabolic syndrome
oxadiazol
Prior art date
Application number
TW094134915A
Other languages
English (en)
Inventor
Nobuhiro Nishigaki
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35517142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200616625(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of TW200616625A publication Critical patent/TW200616625A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW094134915A 2004-10-07 2005-10-06 Agent for prophylaxis or treatment of metabolic syndrome TW200616625A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004294889 2004-10-07
JP2005125373 2005-04-22

Publications (1)

Publication Number Publication Date
TW200616625A true TW200616625A (en) 2006-06-01

Family

ID=35517142

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094134915A TW200616625A (en) 2004-10-07 2005-10-06 Agent for prophylaxis or treatment of metabolic syndrome

Country Status (17)

Country Link
US (1) US20070270477A1 (zh)
EP (1) EP1799203A1 (zh)
JP (1) JP2008515767A (zh)
KR (1) KR20070073872A (zh)
AR (1) AR052015A1 (zh)
AU (1) AU2005290394A1 (zh)
BR (1) BRPI0516246A (zh)
CA (1) CA2583768A1 (zh)
CR (1) CR9074A (zh)
IL (1) IL182055A0 (zh)
MX (1) MX2007003716A (zh)
NO (1) NO20071889L (zh)
PE (1) PE20060971A1 (zh)
RU (1) RU2007116969A (zh)
TW (1) TW200616625A (zh)
UY (1) UY29155A1 (zh)
WO (1) WO2006038722A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007126135A1 (en) * 2006-04-27 2007-11-08 Takeda Pharmaceutical Company Limited Pharmaceutical composition of angiotensin ii antagonists with pioglitazone hcl
JP2008195625A (ja) * 2007-02-08 2008-08-28 Pharma Frontier Kk Ｇ蛋白質共役型レセプター抑制剤および医薬
CA2782224A1 (en) * 2009-11-30 2011-06-03 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Azilsartan organic amine salts, preparation method and use thereof
US20130217778A1 (en) * 2010-07-21 2013-08-22 Herman H. Vandenburgh Methods and compositions for the improvement of skeletal muscle function in a mammal
EP2666773B1 (en) 2011-01-20 2017-07-26 Jiangsu Hansoh Pharmaceutical Co., Ltd. Organic amine salts of azilsartan, preparation method and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
PT914158E (pt) * 1996-04-05 2002-11-29 Takeda Chemical Industries Ltd Combinacao farmaceutica que incorpora um composto que possui actividade antagonista da angiotensina ii e um composto que aumenta a sensibilidade a insulina
PL342684A1 (en) * 1998-03-04 2001-07-02 Takeda Chemical Industries Ltd Preperation featured by reterded release of aii antagonist, production and application of such preparation
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
CA2420055C (en) * 2000-08-25 2010-06-01 Takeda Chemical Industries, Ltd. Fibrinogen-lowering agent
EP1452176A4 (en) * 2001-12-03 2009-01-21 Takeda Pharmaceutical MEANS FOR IMPROVING INSULIN RESISTANCE
JP4484427B2 (ja) * 2001-12-03 2010-06-16 武田薬品工業株式会社 インスリン抵抗性改善剤
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
AU2003256419A1 (en) * 2002-08-21 2004-03-11 Merck & Co., Inc. Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
US7582662B2 (en) * 2002-12-27 2009-09-01 Takeda Pharmaceutical Company Limited Body weight gain inhibitor

Also Published As

Publication number Publication date
US20070270477A1 (en) 2007-11-22
MX2007003716A (es) 2007-04-23
CR9074A (es) 2007-08-28
BRPI0516246A (pt) 2008-08-26
UY29155A1 (es) 2006-02-24
KR20070073872A (ko) 2007-07-10
WO2006038722A1 (en) 2006-04-13
CA2583768A1 (en) 2006-04-13
JP2008515767A (ja) 2008-05-15
AR052015A1 (es) 2007-02-28
AU2005290394A1 (en) 2006-04-13
IL182055A0 (en) 2007-07-24
PE20060971A1 (es) 2006-11-15
NO20071889L (no) 2007-06-26
RU2007116969A (ru) 2008-11-20
EP1799203A1 (en) 2007-06-27

Similar Documents

Publication Publication Date Title
RS20080510A (en) Benzimidazole derivative and use as angiotensin ii antagonist
IL183357A0 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
UA94427C2 (ru) Фармацевтическая композиция для местного лечения неоваскулярных расстройств глаз
MA29799B1 (fr) Administration d'inhibiteurs de dipeptidyl peptidase
CL2011000625A1 (es) Preparación sólida que comprende 2-etoxi-1-((2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil-4-il)metil)-1h-bencimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metilo, un agente regulador de ph y un compuesto antagonista de calcio; y metodos para utilizar y mejorar disolucion del compuesto en la preparacion solida.
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
CL2007001427A1 (es) Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
AR052052A1 (es) Terapia de combinacion
IL216176A (en) Derivatives (3'-fluoro-4'-hydroxymethyl-5 '- (methylsulfonyl) biphenyl-4-yl) -2-phenylalkyl- (h1-imidazole-4-yl) propane-2-ol and pharmaceuticals containing them
TW200616625A (en) Agent for prophylaxis or treatment of metabolic syndrome
WO2007143557A3 (en) Compounds and methods for treating mammalian gastrointestinal parasitic infections
TW200722088A (en) Diabetes remedy
MX2009003912A (es) Metodos y composiciones usando compuestos inmunomoduladores para el tratamiento y manejo de enfermedades bacterianas por espiroquetas y otras bacterias intracelulares obligadas.
TW200833323A (en) Prophylactic or therapeutic agent for alopecia
UA92485C2 (ru) Производная бензамида и ее применение как антагониста ангиотензина ии
SI1904490T1 (sl) Etanolaminska sol N-(3-metoksi-5-metilpirazin-2-il)-2-(4-(1,3,4-oksadiazol-2-il)fenil)- piridin-3-sulfonamida
MX2010005009A (es) Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.
CL2007003281A1 (es) Compuesto 1-(4-metilfenil)dihidro-1h-pirrolo[1,2-a]imidazol-2,5-(3h,6h)-diona; composicion farmaceutica; y uso para el tratamiento terapeutico o preventivo de la neurotoxicidad periferica inducida por quimioterapeuticos.
ZA200711023B (en) Metal salts of 2'-(1h-tetrazol-5-yl)-1.1'-bipheny-4-carboxaldehyde
MX2009004237A (es) Uso de timosina alfa 1 para la preparacion de un medicamento para la prevencion y tratamiento de alergias.
AR062215A1 (es) Inhibidor de trombina activo por via oral
TW200518747A (en) Additional pharmaceutical use
WO2009024820A3 (en) Therapeutic treatment 014
TH82345B (th) สารสำหรับการป้องกัน หรือรักษากลุ่มอาการเมแทบอลิค